The choice isn't that hard.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Both companies now aim to win in the oral weight loss drug market.

Jan 23 (Reuters) - Novo Nordisk's Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared by an analyst on Friday showed. Investors are closely ...

The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Strive Specialities Inc., a major provider of compounded medicines, filed a federal lawsuit against pharmaceutical giants Eli ...